Deutsche Bank reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Friday morning, Borsen Zeitung reports. The firm currently has a GBX 8,300 ($109.18) target price on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on AZN. Credit Suisse Group set a GBX 8,500 ($111.81) target price on AstraZeneca and gave the company a buy rating in a research report on Monday, February 17th. UBS Group set a GBX 6,000 ($78.93) target price on AstraZeneca and gave the company a sell rating in a research report on Monday, March 9th. Morgan Stanley upped their target price on AstraZeneca from GBX 7,400 ($97.34) to GBX 8,100 ($106.55) and gave the company an equal weight rating in a research report on Monday, January 6th. JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a research report on Tuesday, March 10th. Finally, Jefferies Financial Group reiterated a hold rating and set a GBX 7,475 ($98.33) target price on shares of AstraZeneca in a research report on Friday, February 14th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. AstraZeneca currently has a consensus rating of Buy and a consensus target price of GBX 7,862.14 ($103.42).

Shares of LON:AZN traded down GBX 14 ($0.18) during trading on Friday, reaching GBX 6,891 ($90.65). 6,395,407 shares of the company traded hands, compared to its average volume of 2,310,000. The company’s 50 day moving average is GBX 7,243.74 and its two-hundred day moving average is GBX 7,327.66. The firm has a market capitalization of $90.42 billion and a PE ratio of 67.16. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 139.95. AstraZeneca has a 52 week low of GBX 5,626 ($74.01) and a 52 week high of GBX 8,227.88 ($108.23).

The firm also recently disclosed a dividend, which will be paid on Monday, March 30th. Investors of record on Thursday, February 27th will be given a dividend of GBX 146.40 ($1.93) per share. This is an increase from AstraZeneca’s previous dividend of $71.90. This represents a dividend yield of 1.92%. The ex-dividend date is Thursday, February 27th. AstraZeneca’s dividend payout ratio is currently 2.12%.

In other AstraZeneca news, insider Michel Demare acquired 700 shares of the company’s stock in a transaction that occurred on Monday, February 17th. The stock was acquired at an average cost of GBX 7,313 ($96.20) per share, for a total transaction of £51,191 ($67,338.86).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Penny Stocks, Risk and Reward Factors

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.